Ischemix, Inc. Completes Successful Phase 1 Trial of Novel C

CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translati...

Related Keywords

Canada , Montreal , Quebec , David Dewahl , Davida Dewahl Jr , Ischemix Inc , Altasciences Company Inc , Health Affairs , Us Army Medical Research , Department Of Defense Contact Information , Technology Enterprise Consortium Under Award No , Department Of Defense , Development Command , Casualty Care Research Program , Neurotrauma At Combat Casualty Care Research Program , Technology Enterprise Consortium , Technology International , Principal Investigator , Chief Medical Officer , Medical Research , Combat Casualty Care Research Program , Medical Technology Enterprise Consortium , Disease Control , Combat Casualty Care Research , Traumatic Brain Injury Portfolio , Multi Domain Operations , Advanced Technology , Assistant Secretary , Defense Contact Information , Completes Successful Phase , Novel Compound , Treat Traumatic Brain Injury ,